Ballentine Partners LLC purchased a new position in Clover Health Investments, Corp. (NASDAQ:CLOV – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 41,496 shares of the company’s stock, valued at approximately $131,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Forum Financial Management LP lifted its holdings in shares of Clover Health Investments by 33.8% during the third quarter. Forum Financial Management LP now owns 16,077 shares of the company’s stock valued at $45,000 after purchasing an additional 4,061 shares in the last quarter. Steph & Co. increased its stake in shares of Clover Health Investments by 33.3% in the fourth quarter. Steph & Co. now owns 20,000 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares in the last quarter. SignalPoint Asset Management LLC boosted its stake in shares of Clover Health Investments by 6.2% in the fourth quarter. SignalPoint Asset Management LLC now owns 160,074 shares of the company’s stock worth $504,000 after acquiring an additional 9,390 shares during the period. Bleakley Financial Group LLC grew its stake in Clover Health Investments by 98.9% during the third quarter. Bleakley Financial Group LLC now owns 20,090 shares of the company’s stock valued at $57,000 after acquiring an additional 9,988 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in Clover Health Investments during the 3rd quarter valued at approximately $28,000. 19.77% of the stock is currently owned by institutional investors.
Clover Health Investments Price Performance
NASDAQ CLOV opened at $4.82 on Monday. The stock’s fifty day moving average price is $3.48 and its 200 day moving average price is $3.12. Clover Health Investments, Corp. has a 1 year low of $0.61 and a 1 year high of $4.87. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -24.10 and a beta of 1.95.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on CLOV shares. Craig Hallum began coverage on Clover Health Investments in a research report on Tuesday, December 17th. They set a “buy” rating and a $6.00 target price on the stock. UBS Group started coverage on Clover Health Investments in a research note on Monday, October 7th. They set a “neutral” rating and a $4.00 price objective for the company.
Check Out Our Latest Stock Analysis on CLOV
Clover Health Investments Profile
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
Featured Stories
- Five stocks we like better than Clover Health Investments
- Compound Interest and Why It Matters When Investing
- MP Materials: Rare Earth Elements Powering the EV Boom
- Industrial Products Stocks Investing
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Quiet Period Expirations Explained
- Bloom Energy: Powering the Future With Decentralized Energy
Want to see what other hedge funds are holding CLOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clover Health Investments, Corp. (NASDAQ:CLOV – Free Report).
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.